ABBVIE (ABBV) Earnings Date & Reports

Key Takeaways

• Revenue exceeded expectations: AbbVie reported second-quarter net revenues of $16.99 billion, up 10.2% year over year and above the consensus estimate of approximately $16.78 billion.
• Adjusted EPS topped guidance: Adjusted diluted earnings per share (EPS) came in at $3.65, surpassing the company's own guidance range of $3.57–$3.61 and the FactSet consensus of $3.60, and rising 22.9% from the prior-year period.
• Immunology and neuroscience drove growth: Skyrizi sales surged 24.4% to $5.51 billion and Rinvoq climbed 24.5% to $2.53 billion, while the neuroscience portfolio delivered a 20.3% revenue increase to $3.23 billion.
• Full-year EPS guidance was trimmed: AbbVie lowered its 2026 adjusted diluted EPS outlook to $13.87–$14.07 from $13.91–$14.11, citing $0.14 per share of dilution from the planned $10.9 billion acquisition of Apogee Therapeutics.
• Stock declined on the guidance revision: Shares fell approximately 2.5% on the day of the report, as the guidance cut and acquisition-related uncertainty weighed on investor sentiment despite the top- and bottom-line beats.

Earnings Context and Why It Matters

AbbVie's second-quarter report arrived at a pivotal moment for the pharmaceutical giant. The company has been navigating the multi-year decline of Humira—once the world's best-selling drug—due to biosimilar competition, while simultaneously proving that its next-generation immunology therapies, Skyrizi and Rinvoq, can carry the growth baton. This quarter served as a critical progress check on that transition. Beyond immunology, investors were watching for sustained momentum in neuroscience, stabilization in aesthetics, and clarity on how the proposed Apogee Therapeutics acquisition would reshape the near-term financial picture. With AbbVie shares up roughly 14% year-to-date heading into the report, the bar was high, and the market's reaction underscored how sensitive the stock remains to any downward adjustment in the earnings outlook.

Reported Results

AbbVie reported worldwide net revenues of $16.99 billion for the second quarter ended June 30, 2026, representing a 10.2% increase on a reported basis and a 9.5% increase on an operational basis. The top-line figure comfortably exceeded the Wall Street consensus of roughly $16.78 billion.

On the bottom line, GAAP (generally accepted accounting principles) diluted EPS was $2.03, a sharp increase from $0.52 in the prior-year period. Adjusted diluted EPS, which excludes certain items including acquired IPR&D (in-process research and development) and milestone expenses, was $3.65, up 22.9% year over year. That result surpassed both the company's own guidance of $3.57–$3.61 and the FactSet consensus of $3.60, though it landed slightly below some higher sell-side estimates that had clustered near $3.71.

The immunology portfolio remained the standout, generating $8.79 billion in global revenue—a 15.1% increase. Skyrizi led the charge at $5.51 billion, while Rinvoq contributed $2.53 billion. Humira, as expected, continued its decline, falling 35.9% to $756 million. Neuroscience revenue jumped 20.3% to $3.23 billion, powered by Vraylar ($1.07 billion), Botox Therapeutic ($1.04 billion), and the oral migraine franchise of Ubrelvy and Qulipta ($742 million combined). Oncology revenue slipped 1.5% to $1.65 billion, pressured by a 29.4% decline in Imbruvica due to IRA (Inflation Reduction Act) pricing and competitive headwinds. The aesthetics portfolio was essentially flat at $1.28 billion.

AI Screener

For investors seeking to identify opportunities beyond individual earnings reports, Tickeron's AI Screener offers a powerful way to navigate the broader market. The AI Screener is an AI-powered stock and ETF discovery tool that allows traders and investors to filter thousands of equities using customizable criteria such as industry sector, market capitalization, technical indicators, price patterns, volatility metrics, and AI-driven trading signals. Whether you are scanning for breakout candidates, tracking momentum shifts, or hunting for undervalued names with strong fundamentals, the screener helps streamline the research process and surface trade ideas more efficiently than manual screening alone. Explore the AI Screener to see how data-driven filtering can sharpen your market perspective.

Market Reaction and Investor Sentiment

Despite beating on both revenue and adjusted EPS relative to the most widely followed consensus figures, AbbVie shares declined approximately 2.5% on July 31, closing at $250.94 after trading as low as $247.00 intraday. The premarket reaction was even sharper, with the stock briefly down 3.7%.

The sell-off was driven primarily by the downward revision to full-year adjusted EPS guidance, which now stands at $13.87–$14.07 versus the prior range of $13.91–$14.11. While the reduction appears modest on the surface, it reflects a combination of factors that gave investors pause: $0.14 per share in dilution from the Apogee Therapeutics acquisition, partially offset by $0.10 of underlying operational overperformance. The net effect places the midpoint of AbbVie's outlook ($13.97) below the analyst consensus of approximately $14.06–$14.12. Additionally, third-quarter revenue guidance of roughly $17.2 billion came in slightly below some Street forecasts, adding a layer of near-term caution. The stock's reaction suggests that after a strong run, the market was priced for perfection and proved unforgiving of even a modest guidance trim tied to a strategically significant acquisition.

Forward Outlook and Key Factors to Monitor

Looking ahead, AbbVie enters the second half of 2026 with a mixed but largely constructive setup. The company raised its full-year revenue guidance by $300 million to approximately $67.6 billion, marking a cumulative $600 million increase since the start of the year. This reflects management's confidence in the continued momentum of Skyrizi and Rinvoq, both of which are expected to maintain above-20% growth rates across their expanding indications.

A near-term catalyst worth watching is the potential U.S. approval of a subcutaneous induction option for Skyrizi in Crohn's disease, which could broaden patient access and further accelerate uptake. In parallel, U.S. regulatory decisions on Rinvoq for vitiligo and alopecia areata are expected, and AbbVie management has indicated that the combined peak sales opportunity for these two indications alone could approach $2 billion—well above prior expectations.

The Apogee Therapeutics acquisition, expected to close in the third quarter, represents both a strategic opportunity and a near-term overhang. The deal adds zumilokibart, a promising late-stage candidate for atopic dermatitis and other inflammatory conditions, to AbbVie's immunology pipeline, but it also introduces incremental R&D (research and development) spending and requires new debt financing. AbbVie has signaled its intention to return to a net leverage ratio of two times within two to three years post-close.

On the risk side, Humira erosion will remain a persistent headwind, though its relative contribution to total revenue continues to shrink. Oncology faces ongoing competitive and pricing pressure, particularly for Imbruvica, while the aesthetics segment has yet to demonstrate a convincing return to growth. Investors should also monitor the pace of operating expense management as the company balances pipeline investment with acquisition integration. The third-quarter print will offer the next concrete checkpoint on whether AbbVie can sustain its revenue trajectory while absorbing the Apogee dilution without further downward revisions to earnings expectations.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations